Lithium citrate anhydrous
As of the edition of 20 October 2026, Lithium citrate anhydrous is a small molecule: marketed, first approved in 1982 (US); acts on GSK3A, GSK3B and IMPA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Lithonate
- First approved
- 1 January 1982 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Solvay Pharmaceuticals; 2 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Hikma Pharmaceuticals | Later holder | |
| Solvay Pharmaceuticals | Applicant |